vs
Side-by-side financial comparison of ASHFORD HOSPITALITY TRUST INC (AHT) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
ASHFORD HOSPITALITY TRUST INC is the larger business by last-quarter revenue ($259.0M vs $129.7M, roughly 2.0× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -6.0%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -7.7%).
Ashford Hospitality Trust Inc is a U.S.-headquartered real estate investment trust focused on upper-upscale full-service hotel properties across key U.S. urban, suburban and resort markets. Its portfolio holds assets under top global hospitality brands, serving business and leisure travelers, with a focus on long-term value growth and stable shareholder returns.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
AHT vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $259.0M | $129.7M |
| Net Profit | $-69.3M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | -2.6% | -25.0% |
| Net Margin | -26.8% | — |
| Revenue YoY | -6.0% | 73.4% |
| Net Profit YoY | 44.2% | — |
| EPS (diluted) | $-12.85 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $259.0M | $129.7M | ||
| Q3 25 | $266.1M | $164.9M | ||
| Q2 25 | $302.0M | $114.4M | ||
| Q1 25 | $277.4M | $81.7M | ||
| Q4 24 | $275.5M | $74.8M | ||
| Q3 24 | $276.6M | $62.9M | ||
| Q2 24 | $316.5M | $54.1M | ||
| Q1 24 | $303.9M | $41.4M |
| Q4 25 | $-69.3M | — | ||
| Q3 25 | $-60.1M | $25.7M | ||
| Q2 25 | $-30.4M | $-12.8M | ||
| Q1 25 | $-20.0M | $-41.2M | ||
| Q4 24 | $-124.2M | — | ||
| Q3 24 | $-57.9M | $-54.8M | ||
| Q2 24 | $50.3M | $-70.4M | ||
| Q1 24 | $71.6M | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | -2.6% | -25.0% | ||
| Q3 25 | 4.6% | 15.1% | ||
| Q2 25 | 16.3% | -11.1% | ||
| Q1 25 | 22.2% | -52.2% | ||
| Q4 24 | -17.8% | -81.2% | ||
| Q3 24 | 7.3% | -89.3% | ||
| Q2 24 | 42.8% | -125.1% | ||
| Q1 24 | 50.2% | -336.5% |
| Q4 25 | -26.8% | — | ||
| Q3 25 | -22.6% | 15.6% | ||
| Q2 25 | -10.1% | -11.1% | ||
| Q1 25 | -7.2% | -50.4% | ||
| Q4 24 | -45.1% | — | ||
| Q3 24 | -20.9% | -87.1% | ||
| Q2 24 | 15.9% | -130.1% | ||
| Q1 24 | 23.5% | -328.9% |
| Q4 25 | $-12.85 | $0.04 | ||
| Q3 25 | $-11.35 | $0.28 | ||
| Q2 25 | $-6.88 | $-0.14 | ||
| Q1 25 | $-4.91 | $-0.47 | ||
| Q4 24 | $-13.64 | $-0.71 | ||
| Q3 24 | $-12.39 | $-0.70 | ||
| Q2 24 | $2.50 | $-0.91 | ||
| Q1 24 | $5.99 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $66.1M | $93.0M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $-626.4M | $114.8M |
| Total Assets | $2.8B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.1M | $93.0M | ||
| Q3 25 | $81.9M | $110.9M | ||
| Q2 25 | $100.0M | $75.2M | ||
| Q1 25 | $85.8M | $61.9M | ||
| Q4 24 | $112.9M | $58.5M | ||
| Q3 24 | $119.7M | $36.4M | ||
| Q2 24 | $121.8M | $32.3M | ||
| Q1 24 | $111.1M | $43.3M |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.7B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.8B | — | ||
| Q1 24 | $2.9B | — |
| Q4 25 | $-626.4M | $114.8M | ||
| Q3 25 | $-548.7M | $73.6M | ||
| Q2 25 | $-485.5M | $32.7M | ||
| Q1 25 | $-446.1M | $32.8M | ||
| Q4 24 | $-419.2M | $59.1M | ||
| Q3 24 | $-288.4M | $-30.5M | ||
| Q2 24 | $-225.9M | $15.1M | ||
| Q1 24 | $-276.8M | $74.1M |
| Q4 25 | $2.8B | $605.2M | ||
| Q3 25 | $3.0B | $538.6M | ||
| Q2 25 | $3.1B | $555.3M | ||
| Q1 25 | $3.1B | $548.8M | ||
| Q4 24 | $3.2B | $594.1M | ||
| Q3 24 | $3.3B | $504.4M | ||
| Q2 24 | $3.3B | $551.1M | ||
| Q1 24 | $3.5B | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $60.7M |
| Free Cash FlowOCF − Capex | $-86.8M | — |
| FCF MarginFCF / Revenue | -33.5% | — |
| Capex IntensityCapex / Revenue | 27.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-135.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-15.7M | $60.7M | ||
| Q3 25 | $5.5M | $14.3M | ||
| Q2 25 | $16.3M | $5.0M | ||
| Q1 25 | $-25.0M | $-42.2M | ||
| Q4 24 | $-23.6M | $-35.7M | ||
| Q3 24 | $795.0K | $-42.5M | ||
| Q2 24 | $8.0M | $-40.2M | ||
| Q1 24 | $-46.5M | $-119.0M |
| Q4 25 | $-86.8M | — | ||
| Q3 25 | $-226.0K | $14.2M | ||
| Q2 25 | $-3.6M | — | ||
| Q1 25 | $-44.8M | — | ||
| Q4 24 | $-131.6M | — | ||
| Q3 24 | $-21.8M | — | ||
| Q2 24 | $-22.9M | $-40.3M | ||
| Q1 24 | $-80.4M | — |
| Q4 25 | -33.5% | — | ||
| Q3 25 | -0.1% | 8.6% | ||
| Q2 25 | -1.2% | — | ||
| Q1 25 | -16.2% | — | ||
| Q4 24 | -47.8% | — | ||
| Q3 24 | -7.9% | — | ||
| Q2 24 | -7.2% | -74.5% | ||
| Q1 24 | -26.5% | — |
| Q4 25 | 27.5% | — | ||
| Q3 25 | 2.1% | 0.1% | ||
| Q2 25 | 6.6% | — | ||
| Q1 25 | 7.2% | — | ||
| Q4 24 | 39.2% | — | ||
| Q3 24 | 8.2% | 0.0% | ||
| Q2 24 | 9.8% | 0.2% | ||
| Q1 24 | 11.2% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.16× | — | ||
| Q1 24 | -0.65× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AHT
| Occupancy | $190.2M | 73% |
| Food And Beverage | $51.8M | 20% |
| Hotel Other | $16.6M | 6% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
